? FLOW CYTOMETRY SHARED RESOURCE (FCSR) Flow cytometry services are critical for cancer research. Since flow cytometry instrumentation is expensive, and typically requires significant technical expertise, a centralized resource is essential. The mission of the FCSR is to support OSUCCC members and high-impact cancer research projects with high quality cell analysis and sorting capabilities. The FCSR also provides training and regularly host technology-based seminars or workshops to introduce new technology to OSUCCC members. The FCSR continues to strive to be a state-of- the-art cell analysis laboratory that has the following Specific Aims to: 1) provide state-of-the-art equipment and support for high-quality cancer research for OSUCCC members on a fee-for-service basis; 2) continuously work with OSUCCC members to provide substantial technical expertise and training for state-of the-art cytometry instruments to address fundamental questions in cancer research so that researchers can have 24-hour access to flow cytometry instrumentation; and 3) introduce OSUCCC members to new instrumentation, technology and methodologies being developed at the FCSR through a variety of educational outreach activities. The FCSR co- Directors are Jeffrey Chalmers, (Department of Chemical and Biomolecular Engineering), and recently appointed co-Director, Kevin Weller, Associate Director of the Pelotonia Institute of Immuno-Oncology (PIIO) and specifically to develop the Immune Monitoring and Discovery Platform, a cross-cutting shared-resource initiative that integrates shared resources for complex immuno-oncology projects. Further, Dr. Gregory Behbehani (LR) is a Faculty Advisor for the Helios mass cytometer (CyTOF) system. Over the current grant cycle, major changes to the FCSR were to align with the establishment of the PIIO, which will result in a substantial increase in the need for flow cytometry services. To address this need, new instrumentation was purchased including four new instruments including a state-of-the-art Cytek Aurora flow cytometer and a Helios mass cytometer. During this time period, the FCSR contributed to 231 publications (39 >10 impact factor), had 296 users with 34,118 hours of service (83.7% to OSUCCC members), and supported 80 NCI grants (1 K12, 1 K22, 1 K24, 6 P01s, 1 P50, 52 R01s, 1 R03, 7 R21s, 3 R35s, 1 R37, 1 T32, and 5 U01s). In the next funding cycle, the FCSR will support the increasing needs of all OSUCCC strategic priorities, including immuno-oncology, translational genomics, cancer engineering, and cancer prevention and survivorship. The user base will substantially increased requiring new staff and technologies, for example by purchasing an additional Aurora instrument, and increasing cell sorting, cell isolation, and exosome/microvesicle research. In addition, new services under development include development of further exosome characterization and isolation technology. The annual budget of the FCSR is $518,075, yet the CCSG request is $108,261. As such, the FCSR leverages extensive institutional support and seeks only 20.9% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090010
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137
Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Nyankima, A Gloria; Rojas, Juan D; Cianciolo, Rachel et al. (2018) In Vivo Assessment of the Potential for Renal Bio-Effects from the Vaporization of Perfluorocarbon Phase-Change Contrast Agents. Ultrasound Med Biol 44:368-376

Showing the most recent 10 out of 2602 publications